Moving towards precision care for childhood asthma

Area of Science:

• Pediatric Pulmonology
• Allergy and Immunology
• Pharmacogenomics

Background:

• Current asthma guidelines acknowledge diverse asthma endotypes and phenotypes.
• Treatment recommendations primarily focus on age groups, not specific patient phenotypes.
• Phenotype-specific evidence is considered emerging, necessitating further investigation.

Purpose of the Study:

• To review current evidence on managing asthma in school-aged children (5-18 years) based on endotypes and phenotypes.
• To evaluate the impact of endotype and phenotype on treatment responses in pediatric asthma.
• To identify gaps in knowledge and future research directions for personalized asthma management.

Main Methods:

• Systematic review of existing literature on asthma endotypes, phenotypes, and treatment responses in children.
• Analysis of studies examining conventional therapies, omalizumab, and allergen immunotherapy.
• Inclusion of research on severe asthma and emerging therapies like biologics and immunomodulators.

Main Results:

• Studies show varied responses to conventional and biologic therapies based on asthma endotypes/phenotypes.
• Omalizumab and allergen immunotherapy efficacy may differ across phenotypes.
• Emerging therapies show promise in adults, but pediatric data is limited.
• Severe pediatric asthma management requires further phenotype-specific research.

Conclusions:

• Optimal asthma treatment strategies for children are not yet defined and depend on individual characteristics.
• Current evidence on phenotype-specific responses is preliminary due to limited pediatric studies.
• Improved definition of asthma phenotypes and targeted therapies are essential for advancing pediatric asthma care.
• Further pediatric research is needed to validate emerging therapies and personalize treatment approaches.